Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study)

References

• Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 2005;98:599–614
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, et al.; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:689–98
   Google Scholar
• Grundy SM, Cleeman JI, Merz NB, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   Google Scholar
• Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J 2004;148:635–40
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance form serum creatinine. Nephron 1976;16:31–9
   PubMed Web of Science ®Google Scholar
• Ginsberg JSM, Chang BS, Maltarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983;309:1543–46
   PubMed Web of Science ®Google Scholar
• Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191–2
   Google Scholar
• Milionis HJ, Gazi IF, Filippatos TD, et al. Starting with rosuvastatin in primary hyperlipidemia – is there more than lipid lowering? Angiology 2005;56:585–2
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364: 937–52
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152–60
   Google Scholar
• Schuster H, Barter PJ, Stender S, et al.; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705–13
   Google Scholar
• Berne C, Siewert-Delle A; URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol 2005;4: 7
   Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C, et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26:2664–72
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP. Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int J Cardiol 2002;84:53–7
   PubMed Web of Science ®Google Scholar
• Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Doses And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865–74
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.; GREACE Collaborative Group. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627–37
   Google Scholar
• Branchi A, Fiorenza AM, Torri A, et al. Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. Nutr Metab Cardiovasc Dis 2002;12:24–8
   PubMed Web of Science ®Google Scholar
• Asztalos BF, Horvath KV, McNamara JR, et al. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002;43:1701–7
   PubMed Web of Science ®Google Scholar
• Paragh G, Torocsik D, Seres I, et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin 2004;20:1321–7
   PubMed Web of Science ®Google Scholar
• Paolisso G, Barbagallo M, Petrella G, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150:121–7
   PubMed Web of Science ®Google Scholar
• Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the west of Scotland Coronary Prevention Study. Circulation 2001;103:357–62
   Google Scholar
• Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined hyperlipidemia. Am J Cardiol 2005;95:189–93
   PubMed Web of Science ®Google Scholar
• Keane WF, Kasiske BL, O’Donnell MP. Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 1988;47:157–60
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003;14;2084–91
   PubMed Web of Science ®Google Scholar
• Appel GB, Radhakrishnan J, Avram MM, et al.; RENAAL study. Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003;26:1402–7
   Google Scholar
• Tonelli M, Moye L, Sacks FM, et al.; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14: 1605–13
   Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study. J Clin Pathol 2004;57:728–34
   Google Scholar
• McKenney JM. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. Am J Health Syst Pharm 2005;62:1033–47
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004:94:882–8
   PubMed Web of Science ®Google Scholar
• Vidt DG, Cressman MD, Harris S, et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52–60
   PubMed Web of Science ®Google Scholar
• Kaplan RC, Heckbert SR, Furberg CD, et al. Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction. J Clin Epidemiol 2002;55:654–64
   PubMed Web of Science ®Google Scholar
• Chan KY, Boucher ES, Gandhi PJ, et al. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 2004;61:1676–81
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20–8
   Google Scholar
• Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al. The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia. A pilot study involving serial sampling. Curr Med Res Opin 2001;16:269–75
   PubMed Web of Science ®Google Scholar
• Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670–82
   PubMed Web of Science ®Google Scholar
• Marais AD, Firth JC, Bateman ME, et al. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:1527–31
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Lumb PJ, Chik G, et al. Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. Am J Cardiol 2001;87:338–40
   PubMed Web of Science ®Google Scholar
• Milionis HJ, Elisaf MS. Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. Curr Med Res Opin 2000;16:164–70
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041–9
   Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al., for the GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidaemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Am J Kidney Dis 2004;43:589–99
   Google Scholar
• Daskalopoulou SS, Tzovaras V, Mikhailidis DP, et al. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11: 4161–75
   PubMed Web of Science ®Google Scholar
• Youssef F, Gupta P, Seifalian AM, et al. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004;55:53–62
   PubMed Web of Science ®Google Scholar